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Available online 12 February 2011Cervical cytobrushing, biopsy, or lavages have previously been used to collect mononuclear
cells from the female genital tract. Compared with blood, obtaining cells from the female
genital tract is more invasive and generally yields few cells for subsequent immune studies.
Because of the value of including mucosal sampling in HIV vaccine trials, standardisation of
methods for collection, processing, and analysis of immunity from cells derived from the female
genital tract is important. The aim of this study was to assess the effect of transport conditions
on the viability, recovery and antigenic responsiveness of cervical T cells. This was investigated
in cervical cytobrush specimens collected from 215 chronically HIV-infected women.
Cytobrushes were either processed immediately, after cryopreservation, or after 24 h at
37 °C, 4 °C or room temperature. CD3+ T cell numbers were quantiﬁed using Guava automated
cell counting. Viability was assessed using Trypan and Annexin/PI staining. Intracellular
cytokine staining was used to evaluate IFN-γ responses to PMA, PHA and CEF peptides in
cytobrush-derived T cells ex vivo and after delayed processing. In vitro polyclonal expansion of
thawed cervical lymphocytes was conducted for 14 days in the presence of anti-CD3 and IL-2.
We found that CD3+ T cell recovery and viability was similar in cytobrushes processed
immediately or after 24 h irrespective of the conditions at which they were maintained. Fifty
percent of the CD3+ T cells could be recovered after cryopreservation of cytobrushes and these
could be polyclonally expanded in half of the cryopreserved samples. IFN-γ production
following mitogenic stimulation was similar in ex vivo and delayed processing cytobrushes.
Maintaining cytobrushes at 37 °C prior to processing signiﬁcantly improved the detection of
CEF-speciﬁc T cell responses compared to ex vivo.We conclude that cervical cytobrush-derived
T cells are robust and can preserve their viability, phenotype and function over 24 h of mock
transport.
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The genital mucosa is the predominant site of heterosex-
ual HIV transmission and the mucosa-associated lymphoidiseases and Molecular
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Y license.tissue (MALT) of the gut is the site of HIV replication and
massive CD4 T cell depletion during early and established HIV
infection (Li et al., 2005; Mattapallil et al., 2005). Despite the
recognised importance of the genital mucosa and mucosal
immunity in HIV transmission and pathogenesis (Hladik &
McElrath, 2008), the bulk of our current understanding of
correlates of HIV-speciﬁc immunity and pathogenesis are
derived from studies in blood, and most HIV vaccine trials
have focused on measuring responses in blood (Benmira
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strategy studies that have evaluated immunity at mucosal
sites have been conducted at clinical sites with an accredited
laboratory nearby (Karim et al., 2010; McElrath et al., 2010;
Schneider et al., 2007; TOMBOLA group, 2009).
Several methods have been reported to isolate mononu-
clear cells from the genital tract including cervical cytobrush-
ing (Bere et al., 2010a; Bere et al., 2010b; Coombs et al., 2003;
Gumbi et al., 2008; Kaul et al., 2000; Kaul et al., 2003;
Liebenberg et al., 2010; Musey et al., 1997; Musey et al., 2003;
Nkwanyana et al., 2009; Shacklett et al., 2000), cervical biopsy
(TOMBOLA group, 2009), and cervicovaginal lavage (CVL).
Compared with blood, measuring HIV-speciﬁc immune
responses in mucosal tissue associated with the female
genital tract is considerably more invasive, complex, time-
consuming, and generally yields few cells for subsequent
analysis (Nkwanyana et al., 2009; Prakash et al., 2001).
Because of the value of including mucosal sampling in future
vaccine trials, standardisation of methods for collection,
processing, and analysis of immunity from cells derived
from the female genital tract is important. The aim of this
study was to develop and compare protocols for collection
and transport of cervical cytobrushes for preservation of T cell
function. While we conﬁrm that cytobrushing yields rela-
tively few CD3+ T cells for measurement of T cell function, we
show that cytobrush-derived T cells are relatively robust
enough to withstand delayed processing when cells are
maintained at either 37 °C, 4 °C or room temperature based
on maintenance of total CD3+ cells recovered, viability and
ability to respond to mitogenic and antigenic stimulation.
2. Methods
2.1. Study participants
A total of 215 chronically HIV-infected therapy naïve
women and 2 uninfected women were recruited into this
study. Women who were menstruating at the time of
sampling, who were post-menopausal, who had visible or
reported sexually transmitted infection, or who had CD4 T
cell counts b300 cells/ul were excluded from the study. The
study was approved by the University of Cape Town's Faculty
of Health Sciences Research Ethics Committee and informed
written consent was obtained from all volunteers before the
study was initiated.
2.2. Collection of cervical cytobrush specimens
Cervical cytobrush samples were collected according to
the protocol described by Nkwanyana et al. (2009). Brieﬂy,
cervical immune cells were collected from all women under
speculum examination by inserting a Digene cervical sampler
into the endocervical os, rotating 360° and immediately
placing the cytobrush in 3 ml R10 [RPMI 1640 (GibcoTM)
supplemented with 5 mM glutamine, fungazone, penicillin,
streptomycin and 10% FCS (Delta Bioproducts)]. Cytobrush
samples with visible blood contamination (11/215; 5%) or
excessive mucous contamination (21/215; 10%) were ex-
cluded from further analysis. Phenotypic and functional
assessments of cytobrush-derived T cells were conducted in
the remaining 183 samples.2.3. Processing of cytobrush specimens
Samples were transported between the clinic and labora-
tory in temperature-controlled benchtop coolers. Upon arrival
in the laboratory (≤4 h of collection), the cytobrushes were
ﬂushed ~30 timeswith the same 3 ml transportmedia using a
sterile plastic disposable Pasteur pipette and 25 ul of the
suspension was removed for ex vivo CD3+ T cell enumeration
using a Guava automated cell counter. The samples were
divided into four groups to evaluate alternative processing
conditions. Group 1 cytobrushes (n=113) were processed
immediately and used for ﬂow cytometry analysis of immune
subsets by intracellular cytokine staining (function, n=98,
Group 1a) and surface staining (viability, n=15; Group 1b;
ex vivo cytobrushes). Group 2 cytobrushes (n=27) were not
processed immediately but incubated at 37 °C for 24 h prior to
ﬂushing cells off the brush and analysed for phenotype and
function. Similarly, processing of cytobrushes from Groups 3
(n=5) and 4 (n=25) was delayed for 24 h and during this
time, cytobrushes were maintained at 4 °C (to mimic cold
overnight transport) or room temperature (~20 °C; to mimic
overnight transport without refrigeration). After removing
cervical cells off the cytobrush by gentle ﬂushing, cells were
washed once in R10, counted, phenotyped, and functionally
evaluated using a Guava cell counter or FACS Calibur ﬂow
cytometer (BD Biosciences, San Jose, CA), respectively.
2.4. Counting of cervical cytobrush immune subsets
Cervical cytobrush cells were counted using an automated
Guava cell counter according to the method described by
Nkwanyana et al. (2009). CD3-PE (T cells; Guava technolo-
gies) was used to label T cells in each cytobrush samples
which were then counted using a Guava Automated Cell
counter. Brieﬂy, 25 μl cytobrush cells were stained with pre-
titrated CD3-PE monoclonal antibodies and incubated at 4 °C
for 30 min. Cells were washed with 1 ml wash buffer (1% FCS
PBS) and centrifuged at 1500 rpm (437×g) for 5 min. The
supernatant was discarded and a volume of 200 ul Cell Fix
(BD Biosciences) was added to each tube. At least 2000 events
per sample were acquired on the Guava cell counter and data
was analysed using Cytosoft® software (Guava technologies).
In addition, cervix-derived T cells were manually counted
using Trypan Blue staining. Cervical cells were diluted 1:1
with Trypan Blue (Sigma®). Stained cells were placed in
plastic Fast-Read counting chambers (BioSigma) for counting
by Trypan Blue (Sigma®) exclusion and countedwithin 5 min
of staining.
2.5. Freezing and thawing of cervical cytobrush-derived
immune cells
Cervical cytobrush-derived cells from 13 HIV-infected and
2 uninfected women were used to investigate the feasibility
and impact of cryopreservation on recovery of T cells from
cervical cytobrush samples. Cervical mononuclear cells were
ﬂushed off the cytobrush immediately, centrifuged and the
cell pellets gently resuspended. A volume of 500 ul 10% DMSO
FCS (freezing solution) was added drop wise using a Pasteur
pipette. The cell suspension in freezing solution was trans-
ferred into labelled cryovials (Greiner Bio-one) and placed
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then placed at −80 °C for 24 h before transferring to liquid
Nitrogen Storage tanks. Cervical cells were thawed after
1–2 weeks of storage in liquid Nitrogen. Cryovials contain-
ing cervical cytobrush-derived mononuclear cells were
warmed in a 37 °C water bath before adding 1 ml warm R1
(1% FCS in RPMI) drop wise. The suspensions were added to
15 ml Falcon tubes, made up to 10 ml with warm R1 and
centrifuged at 1300 rpm (292×g) for 10 min. The cell pellets
were resuspended in R10 for automated Guava cell counting,
assessment of viability by ﬂow cytometry (n=6 HIV+and
n=2 HIV−) or polyclonal in vitro expansion (n=7 HIV+).
2.6. Assessment of T cell viability using Annexin V and
propidium iodide staining
To determine the impact of cryopreservation on cervical
cytobrush-derived T cell viability, cervical CD3+ T cells were
investigated for expression of Annexin V and propidium
iodide (PI) before and after cryopreservation as described by
Nkwanyana et al. (2009). Thawed cervical cytobrush cells
were either evaluated immediately or rested overnight at
37 °C before viability measurement. Brieﬂy, the viability of
freshly isolated (n=15; ex vivo) cervical cytobrush-derived
T cells was compared with the viability of thawed or thawed/
rested cervical T cells (n=6). Freshly isolated, thawed or
thawed/rested cervical cells were washed twice with 2 ml of
cold PBS at 1500 rpm (437 g) for 5 min and then stained with
CD3-APC, Annexin-FITC and PI-PE (BD Biosciences Cell
Viability Kit) according to the manufacturer's instructions.
The cells were acquired immediately on a FACS Calibur
(BDBiosciences). FlowJo software (Treestar, Ashland, OR) was
used for analysis and compensation.
2.7. Polyclonal in vitro expansion of thawed cervical T cells
To investigate whether cryopreserved cervical cytobrush
T cells were capable of polyclonal in vitro expansion, thawed
cervical CD3+ T cells were cultured in the presence of anti-
CD3 mAb and recombinant human IL-2 as described by Bere
et al. (2010a,2010b). Brieﬂy, thawed cervical cells were
plated into 1 well of a 96-well round-bottomed plates pre-
coated with anti-CD3 mAb (clone UCHT1; ﬁnal concentration
10 ug/ml) at 100 ul per well. Irradiated autologous PBMC
feeders (40 rad) were added at 1x105cells/well (100 ul/well).
Recombinant human IL-2 was added to each well at a ﬁnal
concentration of 100 IU/ml. Cervical T cell lines were in-
cubated at 37 °C 5% CO2 and supplemented every 2 days with
fresh rhIL-2-containing R10 to maintain the ﬁnal concentra-
tion of 100 IU/ml per well. Controls included wells containing
irradiated feeders alone and irradiated feeders stimulated
with anti-CD3 and rhIL-2. Cervical T cell lines were incubated
for 14 days at 37 °C. 5% CO2 and cell numbers weremonitored
by counting after anti-CD3 staining on the Guava automated
cell counter. Cell lines were monitored for contamination and
adjusted to 105 cells/well periodically.
2.8. Intracellular cytokine staining and ﬂow cytometry
Cervical T cells were investigated for their ability to
produce IFN-γ following stimulationwith either CEF peptides,PHA or PMA/Ionomycin by intracellular cytokine staining on a
FACS Caliburﬂow cytometer. PMA/Ionomycin and PHA served
as positive controls while CEF peptides [pooled immunodo-
minant peptides derived from three common human viral
pathogens Cytomegalovirus (CMV), Epstein Barr Virus (EBV)
and inﬂuenza virus (Flu)] served as a speciﬁc antigen since the
epitopes included are restricted by 11 common HLA class I
molecules (Currier et al., 2002) and would therefore be likely
to elicit memory T cell responses. Brieﬂy, cervical cells were
stimulated with (i) PMA/Ionomycin (at a ﬁnal concentration
of 10 μg/ml each; Sigma–Aldrich); (ii) PHA (8 μg/ml; Sigma–
Aldrich); (iii) CEF peptides (1 μg/ml; kindly provided by the
NIH AIDS Reagent repository); and (iii) untreated for 6 h at
37 °C 5% CO2. Brefeldin A (10 μg/ml; Sigma, St. Louis, MO)was
added after the ﬁrst hour. The cells were then washed in 10%
FCS PBS containing 0.01% NaN3 (staining buffer) for 5 min at
1500 rpm (437×g) before staining with anti-CD3, CD4, and
CD8 antibodies (Becton-Dickinson, San Jose, CA) for 30 min on
ice. Cells werewashed, and then ﬁxed and permeabilizedwith
CytoFix/CytoPerm (BD). Following ﬁxation and permeabliza-
tion, surface stained cells were washed with 0.1% Saponin
(Fluka) in staining buffer. The cells were resuspended in the
dead volume after discarding supernatant and stained with
anti-IFN-γ antibody (BD) for 1 h at 4 °C. Finally, cells were
washed and ﬁxed with Cell Fix (BD) and ﬂuorescence was
measured using a FACSCalibur Flow Cytometer (BD Immuno-
cytometry Systems [BDIS]). FlowJo software (Tree Star, Inc.)
was used for analysis and compensation. Since a 4-colour FACS
Calibur ﬂow cytometer was used for these experiments, no
viability marker was used in the panel to exclude dead
cells from analysis (Gumbi et al., 2008). Responsiveness of
cytobrush-derived T cells to the positive control PMA/
Ionomycin was used as a surrogate inclusion criterion for
analysis. Themedian number of CD3+events captured ex vivo
was 867.5 (IQR 280 -1955) and was similar to those captured
at 37 °C, 4 °C and at room temperature, but higher than those
captured after thawing (p=0.007).
2.9. Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 (San Diego, California, USA). Shapiro–Wilks test for
normality was applied to determine the distribution of the
grouped samples. Mann–Whitney U test was applied for
nonparametric independent sample comparisons and Wil-
coxon signed rank tests were applied to matched samples for
nonparametric comparison. Kruskal–Wallis ANOVA tests
were used for non-parametric assessments of variation
between groups, with Dunn's post test applied to test for
the effect of multiple comparisons. For comparison of
frequencies, the X2 test was used to compare groups. All
tests were two-tailed and p-values of b0.05 were considered
signiﬁcant.
3. Results
3.1. Clinical description of cohort
Cervical cytobrush samples from 183 HIV-infected, ther-
apy naïve women were included in this study to compare
alternative conditions for transporting and storage of cervical
Table 1
Clinical description of HIV-infected women.
Group Processing condition N Age CD4 count Log viral load
Years [median (IQR)] Cells/ul [median (IQR)] Log RNA copies/ml [median (IQR)]
1 Ex vivo 113 33 (28–41) 409 (278–605) 4.04 (3.04–4.72)
2 37 °C 27 33 (32–37) 574 (384–783) 3.18 (1.70–4.34)
3 4 °C 5 35 (34–37) 477 (374–490) 4.11 (1.99–5.06)
4 Room Temperature 25 35 (33–38) 436 (340–603) 3.00 (1.70–4.20)
5 Frozen/Thawed 13 34 (31–36) 535 (337–613) 1.70 (1.70–4.58)
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cell yields, viability and function. Table 1 describes the cohort
and conditions evaluated. Of these 183 cervical cytobrushes,
113/183 were evaluated immediately (Group 1 ex vivo;
within 6 h of sampling at the clinic) while 70/183 were
randomly assigned into four groups to investigate the effect of
mock transport or storage on cell recovery and function.
Groups 2–4 cytobrushes were incubated at 37 °C (27/183),
4 °C (5/183) or room temperature (25/183) for 24 h prior to
processing and analysis. Group 5 cytobrushes were processed
and immediately frozen in liquid nitrogen (13/183). The
median age of the women was 34 years (IQR 31–39) and
there was no signiﬁcant difference in the ages of the women
in each of the ﬁve groups (p=0.74). Themedian CD4 count of
the HIV-infected womenwas 434 cells/mm3 (IQR 312–608.8)
and the median log plasma viral load of the HIV-infected
women was 3.7 (IQR 1.7–4.7). There was no signiﬁcant
difference in CD4 counts and plasma viral load between the
groups.
3.2. Impact of delayed cytobrush processing on cervical T cell
recovery and viability
CD3 T cell yields from cervical cytobrush specimens pro-
cessed immediately were compared with those processed
after 24 h (Groups 2–4; Table 2). A median of 65416 (IQR
23424–144720) CD3+ T cells were obtained from cyto-
brushes processed ex vivo. Cervical CD3+ T cell counts
obtained from cytobrushes processed after 24 h and main-
tained at 37 °C, 4 °C, or room temperature did not differ
signiﬁcantly from T cell counts measured ex vivo (p=0.10),
indicating that T cell numbers were relatively stable overTable 2
Impact of delayed cytobrush processing on cervical T cell counts and viability.
Group Processing condition N CD3 counts a
1 Ex vivo 97/183 65416
(25032–140520
2 24 h 37 °C 20/27 38040
(12900–76502)
3 24 h 4 °C 5/5 95280
(41880–259768
4 24 h room temperature 20/25 110400
(34500–272400
5 Frozen/Thawed 10/13 22664
(13968–44672)
a CD3 counts were measured by Guava cell counting using anti-CD3 PE staining.
b Mann-Whitney U tests were used to compare Group 1 data to that in Groups 2
c Viability was assessed using Trypan Blue exclusion or Annexin-PI staining on a F
were considered dead and apoptotic cells were reported in the viable fraction.24 h. Furthermore, none of the cytobrushes evaluated in the
delayed processing experiments became contaminated dur-
ing the 24 h of study.
Cervical cytobrush-derived CD3+ T cells retained a
median of 99.5% (IQR 96.2–100.0%) viable cells at isolation
(Table 2). Ex vivo T cell viability was compared to cervical
cells processed after a 24 h delay. No signiﬁcant reduction in
cervical cell viability was observed in the samples that were
subjected to a delayed processing compared to those pro-
cessed immediately (Table 2).
3.3. Recovery and viability of cervical cytobrush T cells after
cryopreservation
Because of the low yield of cells that can be recovered by
cytobrush from the female genital tract (Nkwanyana et al.,
2009), few studies have evaluated the feasibility and impact of
cryopreservation on cell recovery and viability. We compared
the number of CD3+ T cells isolated from the cervical
cytobrushes of 13HIV-infectedwomenbefore and after storage
in liquid nitrogen. In these samples, the median CD3+ T cell
number obtained ex vivo was 75280 (IQR 37240–90560),
while a signiﬁcantly lower median of 22664 [(IQR 13968–
44672); 48.7% recovery; p=0.005] was recovered after
thawing. Measurements of CD3+ event counts after ICS or
CD3+ T cell numbers by Guava similarly showed that T cell
numbers were relatively stable over the 24 h period at 37 °C,
4 °C and room temperature but that there was a signiﬁcantly
lower T cell yield after cryopreservation.
Annexin V and PI staining were used to evaluate the
viability of CD3+ T cells before freezing and after thawing
(Fig. 1). Fig. 1A shows a representative plot of Annexin Vp-value b N Viability c
(%)
p-value
)
– 33/113 99.95
(96.16–100)
–
0.29 8/25 99
(67.5–100)
0.57
)
0.26 4/5 100
(81.25–100)
0.52
)
0.07 6/25 90
(68.75–100)
0.55
0.01 2/6 92.18
(86.95–97.4)
na
–4 respectively. P-values b0.05 were considered signiﬁcant.
ACS Calibur ﬂow cytometer. For Annexin-PI staining, only PI+Annexin- cells
Fig. 1. Impact of cryopreservation on cervical cytobrush-derived CD3+ T
cell viability measured by Annexin V and propidium iodide staining. (A)
Representative ﬁgure of cervical cytobrush CD3+ T cells stained with
propidium iodide and Annexin V to differentiate live (Annexin−PI−), early
apoptotic (Annexin+PI−), late apoptotic (Annexin+PI+) or dead
(Annexin−PI+) cells. (B) Stacked bar graph showing the proportion of
CD3+ cells that were live, apoptotic or dead in cervical cytobrush samples
from HIV-infected and uninfected women that were (i) processed and
stained immediately (HIV+only), (ii) cryo-preserved then thawed, or (iii)
thawed and rested.
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sample. A median value of 99.5% (IQR 96.16–100.0%) of
cervical cytobrush-derived CD3+ cells were viable ex vivo; of
which, 18.3% co-expressed the late apoptotic markers
Annexin V and PI (IQR 6.5–44.3%), 9.8% expressed Annexin
V only and not PI indicating early apoptosis (IQR 3.3–15.7%;
Annexin+PI−), while 61.4% were not apoptotic and lacked
expression of either marker (Fig. 1B; IQR 39.3–82.60%). We
found that only a small proportion of the cervical T cells were
dead [1.0% Annexin V-PI+; IQR 0–3.2%; Fig. 1B].
After thawing cervical cytobrush cells taken from HIV-
infectedwomen,we found that 96.9% (IQR89.3–99.4) of CD3+
cells recovered were viable and a comparable proportion
of thawed cells expressed early or late apoptotic markers
Annexin V and PI as found on ex vivo T cells (Fig. 1B). If thawed
cells were rested overnight (as is a common practise with
thawed PBMCs prior to functional analysis), we found that the
majority of CD3+ T cells were co-expressing late apoptotic
markers Annexin V and PI (78.5% IQR 78.3–78.6) indicating
that they were in the process of undergoing apoptosis. When
we compared the impact of thawing and resting on cervical
cytobrush cell viability from women who were not infectedwith HIV (Fig. 1B; n=2), we found that viability of thawed
cells was comparable to HIV-infected women but that CD3+
T cells from uninfected women did not exhibit the massive
increase in expression of apoptotic markers after resting as
was noted in cytobrush samples from HIV-infected women.
From this data, conducting analyses on HIV-infected samples
is best performed immediately after thawing.
3.4. In vitro expansion of thawed cervical T cells
We have previously shown that cervical cytobrush-
derived T cells can be expanded in vitro using anti-CD3 and
rhIL-2 (Bere et al., 2010a; Bere et al., 2010b). Here, cervical
cells from 7 HIV-infected women were thawed to investigate
whether cryopreserved cytobrush-derived T cells could be ex-
panded in vitrowith anti-CD3 and rhIL-2 after thawing (Fig. 2).
From these 7 cytobrushes, a median of 80000 CD3+ T cells
(IQR 35040–110880) was isolated prior to cryopreservation.
After thawing, 30% of these CD3+ T cells was recovered (median
of 23680 CD3+ T cells; IQR 13968–47168; p=0.0278). Four of
the 7 thawed cervical samples expanded successfully during
14 days of polyclonal culturewith anti-CD3 and rhIL-2 (Fig. 2). A
median yield of 23845 CD3+ T cells (IQR 12100–91220) was
obtained from these 4 samples after thawing and was ex-
panded to a median of 252291 CD3+ T cells (IQR 190308–
701000; 10-fold; p=0.0286) after 14 days of culture.
3.5. Impact of delayed cytobrush processing on cervical T cell
function
We investigated the impact of cytobrush handling and
processing on the ability of cervical T cells to produce IFN-γ
following stimulation with PMA/Ionomycin (positive con-
trol). The rate of PMA/Ionomycin failure (no production of
IFN-γ following PMA stimulation) was determined in cervical
CD8 and CD4 T cells processed immediately ex vivo (n=98)
or subjected to delayed processing [24 h at 37 °C (n=24),
4 °C (n=5) or room temperature (n=22)]. We found that
ex vivo CD3 cell counts in cervical cytobrush samples cor-
related signiﬁcantly with the frequency of T cells producing
IFN-γ following stimulation with PMA/Ionomycin (Rho=0.5,
Pb0.0001). Furthermore, cervical samples which failed to
respond to PMA/Ionomycin had signiﬁcantly lower CD3+
events [median 18 (IQR 4–143)] than cytobrush samples
that yielded positive IFN-γ responses to PMA [median 98
(IQR 6–154); Fig. 3; p=0.0007]. From this ﬁnding, samples
with CD3+ event counts b100 or were unresponsive to PMA/
Ionomycin were excluded from further analysis.
No signiﬁcant differences were observed between the rate
of PMA/Ionomycin failure by CD8 or CD4 T cells in cervical
samples subjected to delayed processing after 24 h at 37 °C,
4 °C or room temperature compared to those processed
immediately (Table 3). Furthermore, the odds of obtaining a
positive PMA response after 24 h at any of the mock transport
conditions were similar to that ex vivo (Table 3). In addition,
delayed processing (using any of the conditions tested) did
not signiﬁcantly alter the magnitude of PMA/Ionomycin-
stimulated IFN-γ responses by CD8+ or CD4+ T cells
compared to ex vivo (Fig. 4 left panels). Similarly, we found
that delayed processing did not result in signiﬁcantly reduced
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Fig. 2. In vitro expansion of thawed cervix-derived T cells. Kinetics of CD3+ T cell expansion from 4 cryo-preserved and thawed cervical cytobrush samples tha
were polyclonally expanded with anti-CD3 and rhIL-2 for 14 days.
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stimulation with PHA (data not shown).
In addition to IFN-γ responses tomitogens PMA/Ionomycin
and PHA,we evaluated the ability of cervical cytobrush-derived
T cells to produce IFN-γ in response to CEF peptides, a pool of
common viral epitopes from Cytomegalovirus, Epstein–Barr
virus and Inﬂuenza virus (Currier et al. 2002). CEF-speciﬁc
responses were rarely observed in the female genital tract
ex vivo, with dual PMA/Ionomycin- and CEF-speciﬁc responsesCD
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Fig. 3. Impact of cervical cytobrush T cell number on the magnitude of IFN-γ
responses to PMA/Ionomycin. Cervical cells from HIV-infected women were
assayed ex vivo for IFN-γ production in response to stimulation with PMA
Ionomycin. The number of cervical CD3+ T cell events captured in cytobrush
samples that failed to respond (PMA−) or responded to PMA/Ionomycin
(PMA+). Spearman Rank tests were used to test correlations while the
Mann–Whitney U test was used to compare independent groups. Pb0.05
was considered signiﬁcant./tdetectable in theCD8+andCD4+Tcell populations of only 2/18
and 1/18 women respectively (Table 4). Interestingly, the
odds of detecting a response to CEF was generally higher in
cervical T cells subjected to delayed processing (Table 2). Even
so, themagnitudes of PMA/Ionomycin-speciﬁc IFN-γ responses
were consistently higher than CEF-speciﬁc responses in the
cervical T cells (Fig. 4). Despite the ﬁnding that delayed
processing did not reduce T cell responses to PMA/Ionomycin
compared to cells processed immediately, the magnitude of
IFN-γ responses to CEF by cells held at 37 °C for 24 h was
signiﬁcantly higher than cells processed immediately (pb0.001
for CD8+ and CD4+ T cells; Fig. 4). This result was similar in the
blood for CD8+ T cells (p=0.04), and was observed as a trend
in the CD4+ population (p=0.08; data not shown). These
observations suggest that cervical T cell responses to viral
antigensmaybebest detectedwhen samples are transported at
37 °C rather than at the other conditions tested.
4. Discussion
It is widely accepted that understanding T cell-mediated
immunity to HIV in the female genital tract is important in
devising prevention strategies to combat the epidemic
(Abdool Karim et al., 2010; Hasselrot, 2009; Hladik &
McElrath, 2008; Shattock et al., 2008). Despite the recog-
nised importance of incorporating mucosal testing of HIV
vaccine-induced responses, mucosal sampling typically
yields few cells and most analyses that have been
performed were carried out ex vivo in laboratories close to
the clinics from which samples were obtained (McElrath
et al., 2008; Karim et al., 2010). Since HIV vaccine efforts
involve clinical sites around the globe, it is important to
thoroughly evaluate and understand the robustness of
cellular responses from currently available mucosal sam-
ples and the feasibility of cryopreservation or delayed pro-
cessing of such specimens. We and others have previously
shown that cervical cytobrushing provides a useful means
of obtaining mononuclear cells from the female genital tract
for ex vivo measurement of HIV-speciﬁc T cell responses
Table 3
Impact on delayed cytobrush processing on cervical T cell responses to PMA/Ionomycin.
T cell
subset
Transport
conditions
N a Number of
failures b/N
Percentage Odds ratio of positive response
with delayed processing
[OR (95% CI)]
p-value c
CD8 Ex vivo 67/98 22/67 32.8 – –
37 °C 18/24d 4/18 22.2 1.59 (0.4637–5.444 0.46
4 °C 3/5 1/3 33.3 0.98 (0.8399–11.38) 0.99
Room temp 20/22d 5/20 25.0 1.47(0.4721–4.557) 0.51
CD4 Ex vivo 67/98 20/67 29.9 – –
37 °C 18/24d 7/18 38.9 0.61 (0.2026–1.824) 0.37
4 °C 3/5 1/3 33.3 0.85 (0.07290–9.936) 0.90
Room temp 20/22 d 8/20 40.0 0.64 (0.2264–1.800) 0.39
a Number of samples with event counts N100.
b Cervical samples failing to respond (N1.5% IFN-γ responsive cells) to the positive control (PMA/Ionomycin stimulation) were not suitable for further analysis.
c Chi-squared analysis was used to compare groups to ex vivo. P-values b0.05 were considered signiﬁcant.
d Where mucous contamination prevented accurate ICS analysis in 3/27 samples kept at 37 °C and in 3/25 samples kept at room temperature.
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Kaul et al., 2003; Liebenberg et al., 2010; Musey et al., 2003;
Nkwanyana et al., 2009; Quayle et al., 2007; Shacklett et al.,
2000). Here we have investigated whether cervical T cells,
obtained by cytobrushing, could be subjected to delayed
processing or cryopreservation without loss of cell number,PMA/Ionomycin
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Fig. 4. Impact of delayed processing on the magnitude of cervical T cell IFN-γ respon
(bottom panels) T cells were stimulated with PMA/Ionomycin (left panels) or CEF
37 °C, 4 °C or room temperature. Each bar represents the median and IQR net percent
cytobrush samples with N100 CD3+ events. Kruskal–Wallis tests were used for non
applied to test for the effect of multiple comparisons. P-values b0.05 were considerviability or function. We found that cervical cytobrushes
processed immediately yielded a median of 65416 CD3+
T cells with a median viability of 99.95%. Neither CD3 T cell
recovery nor viability was signiﬁcantly different between
cytobrushes subjected to a delayed processing compared to
those processed immediately.CEF
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ses to PMA/Ionomycin or CEF peptides. Cervical CD8+ (top panels) and CD4+
peptides (right panels) immediately (ex vivo) or after delayed processing at
age CD8 or CD4 T cells producing IFN-γ in response to PMA or CEF peptides in
-parametric comparison of variation between groups, with Dunn's post test
ed signiﬁcant.
Table 4
Impact of delayed cytobrush processing on cervical T cell responses to CEF peptide pool.
T cell
subset
Transport
conditions
N a Number of
failures b/N
Percentage Odds ratio of positive response
with delayed processing
[OR (95% CI)]
p-value c
CD8 Ex vivo 18 16/18 88.9 –
37 °C 12 3/12 25.0 24.0 (3.4–171.6) 0.00
4 °C 2 1/2 50.0 8.00 (0.3–184.5) 0.14
Room temp 15 10/15 66.7 4.00 (0.6–24.7) 0.12
CD4 Ex vivo 18 17/18 94.4 –
37 °C 11 3/11 27.3 45.3 (4.–507.1) 0.00
4 °C 2 1/2 50.0 17.0 (0.6–524.2) 0.05
Room temp 12 7/12 50.0 12.1 (1. 2–123.7) 0.02
a Number of PMA-responsive samples concomitantly stimulated with CEF-peptides.
b Cervical samples failing to respond (≤0% IFN-γ responsive cells) to the CEF-peptide stimulation.
c Chi-squared analysis was used to compare groups to ex vivo. P-values b0.05 were considered signiﬁcant.
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can impact signiﬁcantly on cellular composition and func-
tional response proﬁle of mononuclear cells derived from
blood (Betensky et al., 2000; Bull et al., 2007; Reimann et al.,
2000). Bull et al. (2007) showed that reducing the time taken
from venipuncture to PBMC isolation has important effects on
T cell viability, recovery and cytokine function after cryo-
preservation. There have been no such studies for isolation of
cytobrush-derived T cells from the female genital tract. We
found that approximately 50% of the cervical T cells could be
recovered after cryopreservation, but that thawed cells were
comparable in viability to those processed immediately. The
most likely explanation for the cell loss following cryopres-
ervation was the initial composition and viability of the
cytobrush sample. Cervical cytobrush processing typically
yield few CD3+ T cells, and large frequencies of isolated cells
express markers of apoptosis such as CD95 (Liebenberg et al.,
2010). These apoptotic cells have compromised cell mem-
branes and would therefore be more susceptible to cell injury
by the formation of intracellular and extracellular ice than
healthy cells with stronger, intact membranes. In addition,
these thawed cervical T cells from HIV-infected women were
found to rapidly express apoptotic markers Annexin V and PI
indicating that recovered cells were unlikely to be useful for
subsequent functional analysis. Although the recovered low
cell yields would not support subsequent functional studies,
we show that ~50% of cryo-preserved samples could be
polyclonally expanded to improve T cell yields. Given that
ex vivo yields were relatively low and cryopreservation
further reduced this by approximately half, the potential
bottleneck in T cell clonality imposed by these sampling and
storage issues restricts the usefulness of this approach.
We show that the number of CD3+ T cells isolated from
cytobrushing and captured by ﬂow cytometry predicts the
frequency of IFN-γ responses following PMA/Ionomycin
(positive control) and that cytobrush samples which fail to
respond to the positive control generally have CD3 counts b100
events. We describe here a useful tool based on ex vivo CD3
counts for predicting ofwhether cytobrush sampleswill pass or
fail the assay positive control. Based on this cut-off, however,
approximately half of the 98 cervical samples from HIV-
infected women were adequate for use in further analysis.
IFN-γ production in response to stimulation with mito-
gens PMA/Ionomycin and PHA as well as with viral antigenpeptide pool CEF was assessed ex vivo and following delayed
processing. Similar to lymphocyte recovery and viability over
time, the ability of cervical T cells to produce IFN-γ following
PMA/Ionomycin and PHA stimulation was similar in ex vivo
experiments and following delayed processing. However,
incubating cytobrush samples at 37 °C prior to processing
and analysis signiﬁcantly improved our ability to detect
CEF-speciﬁc CD4 and CD8 T cell responses compared to
ex vivo or holding samples for 24 h at room temperature.
In a trial setting, study participants are not always located
in the immediate vicinity of research institutions equipped to
assess immune cell phenotype and function, and transport of
biological samples has been an inevitable part of most of the
large vaccine trials to date. Analyses of genital mucosal
immune responses are especially difﬁcult because of the low
yield of cervical T cells that can be isolated from the female
genital tract. We report that cervical cytobrush-derived T cell
viability and recovery is relatively stable in cytobrushes only
processed after a 24 h delay (mock transport) when samples
are maintained at either 37 °C, 4 °C and room temperature
(~20 °C). Although cryopreservation of cytobrush-derived
mucosal T cells halves the number of T cells available for
analysis, thawed T cell yields can be improved from
approximately half of the women by polyclonal expansion.
Although it is widely recognised that cervical cytobrush
samples yield few cells for in depth analysis of genital tract
immune responses, the ﬁndings from this study suggest that
immune cells isolated in this way are relatively robust and
will maintain immune phenotype and function during
overnight transport between clinical sites and laboratory.
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